Your CV & LinkedIn profile are your digital handshake in the professional world๐ค In todayโs...
๐๐ซ๐๐ฌ๐ข๐ฌ ๐๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ๐ฌ ๐๐๐๐ฎ๐ซ๐๐ฌ $78 ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ญ๐จ ๐๐ฎ๐ฉ๐ฉ๐จ๐ซ๐ญ ๐.๐. ๐๐๐ฎ๐ง๐๐ก ๐จ๐ ๐๐ฅ๐จ๐ฌ๐ข ๐๐จ๐ซ #๐๐ซ๐๐ฌ๐๐ฒ๐จ๐ฉ๐ข๐
๐ฐ Nearly a year after receiving FDA approval, Orasis Pharmaceuticals has successfully raised $78 million in financing to back the U.S. commercial launch of its ground breaking product, Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%. This preservative-free eye drop, originally developed under the name CSF-1, is specifically designed to treat presbyopiaโa common age-related condition that affects near vision.
๐ The new funding will be instrumental in bringing Qlosi to the market, supporting its launch and expanding its reach across the country. This development comes at a time when the pharmaceutical industry is focusing on innovative solutions to meet the growing needs of patients with presbyopia. With Qlosiโs approval, Orasis is positioning itself as a key player in this expanding market.
